Compare Stocks → A new way to collect income from stocks (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVGRNASDAQ:NVIVNASDAQ:NXGL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVGRAvinger$3.81-3.1%$3.39$2.50▼$18.00$6.06M1.2618,402 shs12,003 shsNVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shsNXGLNEXGEL$2.18+0.5%$2.43$1.40▼$3.14$13.58M0.6819,149 shs10,190 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVGRAvinger-3.05%+3.53%+29.59%+34.63%-56.21%NVIVInVivo Therapeutics0.00%0.00%0.00%-50.67%-75.70%NXGLNEXGEL+0.46%0.00%-17.74%-5.22%+38.69%The Hard Truth About Investing For Retirement (Ad)Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVGRAvinger2.3615 of 5 stars3.55.00.00.01.40.80.6NVIVInVivo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANXGLNEXGEL0.1601 of 5 stars0.03.00.00.00.03.30.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVGRAvinger3.00Buy$5.0031.23% UpsideNVIVInVivo TherapeuticsN/AN/AN/AN/ANXGLNEXGELN/AN/AN/AN/ACurrent Analyst RatingsLatest AVGR, NXGL, and NVIV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2024AVGRAvingerHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVGRAvinger$7.65M0.79N/AN/A($4.53) per share-0.84NVIVInVivo TherapeuticsN/AN/AN/AN/A$6.48 per shareN/ANXGLNEXGEL$4.09M3.32N/AN/A$0.90 per share2.42Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVGRAvinger-$18.32M-$26.34N/AN/AN/A-239.41%N/A-106.16%5/8/2024 (Estimated)NVIVInVivo Therapeutics-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/ANXGLNEXGEL-$3.16M-$0.56N/A∞N/A-77.19%-49.49%-30.50%5/20/2024 (Estimated)Latest AVGR, NXGL, and NVIV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2024Q4 2023AVGRAvinger$0.64-$3.93-$4.57-$3.93$2.52 million$1.91 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVGRAvingerN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/ANXGLNEXGELN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVGRAvingerN/A0.630.36NVIVInVivo TherapeuticsN/A14.3014.30NXGLNEXGEL0.101.981.46OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVGRAvinger18.30%NVIVInVivo Therapeutics13.78%NXGLNEXGEL2.21%Insider OwnershipCompanyInsider OwnershipAVGRAvinger11.40%NVIVInVivo Therapeutics2.45%NXGLNEXGEL27.15%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVGRAvinger681.59 million1.41 millionNot OptionableNVIVInVivo Therapeutics63.11 million3.03 millionNot OptionableNXGLNEXGEL126.23 million4.54 millionNot OptionableAVGR, NXGL, and NVIV HeadlinesSourceHeadlineNEXGEL CEO to Spotlight Company at Planet MicroCap Showcasemsn.com - April 21 at 9:11 AMNEXGEL to Present at the Planet MicroCap Showcase: VEGAS 2024, May 1 & 2, 2024finance.yahoo.com - April 18 at 12:36 PMNEXGEL (NXGL) Price Target Decreased by 14.29% to 6.12msn.com - April 17 at 6:30 AMABBV Mar 2025 180.000 putfinance.yahoo.com - April 4 at 9:20 PMNexGel Inc: Sustained Buy Rating Amid Growth and Strategic Positivitymarkets.businessinsider.com - April 3 at 1:20 PMNEXGEL's Engineered Growth: A Triumph in Operational Efficiency and Strategic Partnershipsmsn.com - April 3 at 8:19 AMNEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Yearglobenewswire.com - April 1 at 7:50 AMNEXGEL Announces Q4 and Full-Year 2023 Earnings Call Datemsn.com - March 31 at 8:01 PMNEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holidayglobenewswire.com - March 27 at 9:00 AMNEXGEL Sets Date for Q4 and Full-Year 2023 Earnings Revealmsn.com - March 25 at 4:17 AMNEXGEL to Report Fourth Quarter and Full Year 2023 Financial Results on March 28thglobenewswire.com - March 21 at 9:00 AMNEXGEL to Present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12thglobenewswire.com - March 4 at 8:30 AMNEXGEL (NXGL) Price Target Increased by 16.67% to 7.14msn.com - February 24 at 5:59 PMNEXGEL Raises Capital, Strengthens Balance Sheet Amid Growth Opportunitiesmsn.com - February 23 at 6:49 AMNEXGEL Announces $975,000 Registered Direct Offering Led by Insidersfinance.yahoo.com - February 21 at 9:06 PMNEXGEL to Present at The Microcap Conference, January 30th through February 1stfinance.yahoo.com - January 18 at 9:18 AMNEXGEL Subsidiary, CG Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024finance.yahoo.com - January 9 at 12:43 PMNEXGEL Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North Americafinance.yahoo.com - December 11 at 1:03 PMAnalysts Are Bullish on Top Healthcare Stocks: Veeva Systems (VEEV), Neurocrine (NBIX)markets.businessinsider.com - December 7 at 10:37 PMNEXGEL Acquires Kenkoderm Psoriasis Skincare Linefinance.yahoo.com - December 5 at 12:41 PMNexgel (NXGL) Price Target Increased by 20.00% to 6.12msn.com - November 27 at 6:36 PMNEXGEL, Inc. (NASDAQ:NXGL): When Will It Breakeven?finance.yahoo.com - November 26 at 1:27 PMNEXGEL, Inc. (NASDAQ:NXGL) Q3 2023 Earnings Call Transcriptinsidermonkey.com - November 20 at 12:03 PMNEXGEL GAAP EPS of -$0.10 beats by $0.02, revenue of $1.2M in-linemsn.com - November 13 at 9:08 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAvingerNASDAQ:AVGRAvinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.InVivo TherapeuticsNASDAQ:NVIVInVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.NEXGELNASDAQ:NXGLNEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.